{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:28:24Z","timestamp":1791401304525,"version":"4.3.3"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.1001\/jamaoncol.2022.0238","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T15:00:40Z","timestamp":1649948440000},"page":"910","source":"Crossref","is-referenced-by-count":62,"title":["Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma"],"prefix":"10.1001","volume":"8","author":[{"given":"Giuseppe","family":"Procopio","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangela","family":"Sepe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Claps","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[{"name":"Oncology Unit, University Hospital of Parma, Parma, Italy"},{"name":"Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guadalupi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Trial Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lalli","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Trial Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Fuc\u00e0","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"cbr220004r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101891","article-title":"Collecting ducts carcinoma: an orphan disease. Literature overview and future perspectives.","volume":"79","author":"Pagani","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"cbr220004r2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"cbr220004r3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial.","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"cbr220004r4","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/j.clgc.2018.03.010","article-title":"Management of metastatic collecting duct carcinoma: an encouraging result in a patient treated with cabozantinib.","volume":"16","author":"Mennitto","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"cbr220004r5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s10157-012-0589-3","article-title":"Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.","volume":"16","author":"Procopio","year":"2012","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"cbr220004r6","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"12","key":"cbr220004r7","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1001\/jamaoncol.2021.4544","article-title":"Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma.","volume":"7","author":"Hirsch","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"cbr220004r8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"cbr220004r9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"cbr220004r10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma.","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"cbr220004r11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020.","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"cbr220004r12","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1093\/annonc\/mdt423","article-title":"Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.","volume":"24","author":"P\u00e9cuchet","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"cbr220004r13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","article-title":"A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma.","volume":"71","author":"Fern\u00e1ndez-Pello","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"cbr220004r14","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.juro.2007.01.063","article-title":"Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d\u2019Etudes des Tumeurs Uro-G\u00e9nitales) study.","volume":"177","author":"Oudard","year":"2007","journal-title":"J Urol"},{"key":"cbr220004r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.04.007","article-title":"Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: a prospective, multicentre, single-arm, phase 2 study.","volume":"100","author":"Sheng","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2791274\/jamaoncology_procopio_2022_br_220004_1655232110.96526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T15:02:46Z","timestamp":1655391766000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2791274"}},"subtitle":["Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)"],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.0238","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}